



# EXCELLENCE in Oncology

Translating research into best patient care

## SCIENTIFIC PROGRAMME

Excellence in Oncology 2012 is a groundbreaking international conference in the field of Oncology and Cancer Research that recruits the leading thought-leaders to present their latest scientific findings, as they relate to clinical practice. The vision is simple, to provide a forum for an honest, insightful and comprehensive evidence-based update that allows physicians to deliver the best possible care and advice to their patients. Following on from the resounding success of the 2010 launch event Excellence in Oncology 2012 will once again be research-based and solution-focused in its quest to provide the latest thinking and clinical solutions in oncology.

Excellence in Oncology 2012 programme has been designed by the leading global oncologists, the 'who's who' of international cancer medicine experts, and produced exclusively for their peers and colleagues to collectively learn from latest developments and discoveries. The aim of the meeting is to be the one-stop-shop for all cancer specialists and the meeting is characterised by excellence in content, speakers and delivery.

## MAIN SCIENTIFIC PROGRAMME

The main scientific programme, which will take place from 23 to 25 February 2012, will feature numerous interactive, practical and networking sessions ie. clinical case workshops, special sessions, scientific symposia, clinical case workshops and keynote lectures. The main topics addressed by EIO 2012 are:

- Breast cancer
- Gastrointestinal / colorectal cancer
- Gastrointestinal / non-colorectal cancer
- Genetics
- Gynaecological cancer
- Haematological malignancies
- Melanomas
- Neuro-oncology
- Novel therapeutics
- Psycho-oncology
- Radiation oncology
- Sarcomas
- Screening
- Surgical oncology
- Thoracic Oncology
- Urogenital cancer

## INSTITUTE OF EXCELLENCE IN ONCOLOGY WORKSHOPS

Wednesday 22 February 2012

The Institute of Excellence in Oncology Workshops provides the opportunity to fellows and trainees from developing countries to present their work to an expert panel from the IEO Workshop Faculty and gain valuable feedback and advice for their professional development. Bursaries are provided to allow participation in the Workshops. The Workshops aim to help young oncologists learn:

- how to competently write and present a case study and/or clinical research at international meetings
- how to apply for grant or bursary award

Main topics for 2012 are: breast cancer, lung cancer, gynaecological cancer and genitourinary cancer.

The Workshops faculty comprises of: **Prof Christopher Logothetis**, MD Anderson Cancer Center, USA – Faculty Chairman; **Prof Stephen Johnston**, Royal Marsden Hospital Hospital, UK; **Prof Jonathan Ledermann**, UCL Cancer Research UK Centre, UK; **Dr Gary Middleton**, Royal Surrey County Hospital NHS Foundation Trust, UK

## EXCELLENCE IN ONCOLOGY SUMMIT

The vision of the Summit emerged out of discussions following the inaugural Excellence in Oncology meeting and it has been designed as a vehicle for a constructive dialogue between the key opinion leaders in oncology and those in the Pharma industry. The purpose of the Summit is to identify current problems, suggest credible solutions and formulate how best to implement them. Future editions will build on this by including patient group representatives, interaction with policymakers and direct recommendations. This 3-hour dialogue will focus on the topic of personalised medicine. It aims to be an open exchange of ideas with a view to creating opportunity to make advances in realising the potential of personalised medicine in the treatment of cancer. The EIO Summit has been developed by:

**Prof Christopher Logothetis**, Chairman, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, USA  
**Prof Matti Aapro**, Dean of the Multidisciplinary Oncology Institute, Clinique de Genolier, Switzerland.





**MAIN SCIENTIFIC PROGRAMME**

**Thursday, 23 February 2012**

as per 22 November 2011

	HALL I	HALL II	HALL III	HALL IV
8.30-9.30	<p><b>CLINICAL CASE WORKSHOP</b>  <b>Management of 1st line NSCLC after 4 cycles chemotherapy and stable disease</b>                      Moderator: Sanjay Popat                      Discussants:  <b>Maintenance therapy is standard of care, Jan van Meerbeeck</b>  <b>Maintenance therapy is not standard of care, Thierry Le Chevalier</b></p>	<p><b>CLINICAL CASE WORKSHOP</b>  <b>Decision making in the treatment of recurrent ovarian cancer</b>                      Moderator: Jonathan Ledermann                      Discussants:  <b>Management of end-stage recurrent ovarian cancer, Marcia Hall</b>  <b>About surgical aspects of recurrent ovarian cancer treatment, Philipp Harter</b></p>	<p><b>CLINICAL CASE WORKSHOP</b>  <b>Breast cancer</b>                      Moderator: Stephen Johnston                      Discussant: Bhawna Sirohi*</p>	<p><b>CLINICAL CASE WORKSHOP</b>  <b>Decision making in prostate cancer progressing on ADT</b>                      Moderator:                      Chris Logothetis                      Discussants:                      Peter R. Carroll*                      Eleni Efsthathiou*                      Padamane Sharma*</p>
9.30-11.30	<p><b>ESSO SPECIAL SESSION</b>  <b>Surgical treatment of metastatic cancer</b>                      Chairs: Graeme Poston and Bernard Nordlinger                      Speakers: <b>Liver metastases: resection vs. Ablation, Theo Ruers*</b>  <b>Lung metas tasis resection, Tom Treasure</b>  <b>Peritoneal metastases, Dominic Elias</b>  <b>Resection non-CRC/non-NET, Graeme Poston</b></p>		<p><b>ESTRO SPECIAL SESSION</b>  <b>New trends in practicing radiation oncology</b>                      Chair: Harry Bartelink                      Speakers: <b>Stereotactic radiotherapy for lung cancer, Jose Belderbos</b>  <b>Translational research in radiotherapy, Andrian Begg</b>  <b>Concomitant radiotherapy and chemotherapy, the standard of care?, Jean Bourhis</b>  <b>Fractionation schedules in lung and breast cancer, John Yarnold</b>  <b>Partial breast irradiation state of the art?, Roberto Orecchia</b></p>	
11.30-12.00	<b>COFFEE BREAK</b>			
12.00-13.15	<p><b>CURRENT ISSUES IN ONCOLOGY</b>  <b>Loco-regional oesophageal cancer</b>                      Chair: Peter Schlag                      Speakers: <b>Squamous cell vs adenocarcinoma, Peter Malfertheiner</b>  <b>Surgery alone, Steven R DeMeester</b>  <b>Neo-adjuvant/adjuvant chemotherapy, Peter Schlag</b>  <b>Definitive radiotherapy/chemoradiotherapy, Jean-Francois Bosset*</b></p>		<p><b>CLINICAL QUESTIONS FOR HODGKIN LYMPHOMA</b>                      Chair: Volker Diehl                      Speakers: <b>The role of PET/CT in directing the treatment of advanced HL, Andrea Gallamini</b>  <b>The current position of radiotherapy in early stages HL, Theodore Girinsky</b>  <b>The clinical relevance of the CD68+ve macrophages in HL, Randy Gascoyne</b></p>	
13.15-14.30	<p><b>SCIENTIFIC SYMPOSIUM</b>  <b>Neuroendocrine tumours</b>                      Chair: Elisabeth De Vries                      Speakers: <b>In the land of interferon for neuroendocrine tumours. Is interferon old or new?, Kjell Oberg</b>  <b>mTtor inhibition and beyond as novel treatment of neuroendocrine tumours, Elisabeth De Vries</b>  <b>Novel approach with angiogenesis inhibitors for neuroendocrine tumours, Eric Raymond</b></p>		<p><b>SCIENTIFIC SYMPOSIUM</b>  <b>New developments; image guided therapy</b>                      Chair: Patricia Price                      Speakers: <b>Irreversible electroporation using Nanoknife and advance in radiofrequency ablation, Edward Leen</b>  <b>HIFU for a range of tumours, Rick Popert</b>                      title to be announced, Anders Wennborg</p>	
14.30-15.30	<b>LUNCH BREAK</b>			
15.30-16.15	<p><b>KEYNOTE LECTURE</b>  <b>Value as a new standard for drug approval in cancer</b>                      Speaker: John Marshall</p>	<p><b>CURRENT ISSUES IN ONCOLOGY</b>  <b>Renal cell cancer</b>                      Speaker: J. Wagstaff*</p>		
16.15-16.30				
16.30-17.00				
17.00-17.15			<p><b>CLINICAL QUESTIONS FOR PROSTATE CANCER - SESSION I</b>                      Chair: Chris Logothetis                      Speakers:  <b>Introduction: New insights in the clinical and basic mechanisms of prostate cancer progression, Chris Logothetis</b>  <b>Localised Cancer: Changes in the clinical understanding of prostate cancer that frames therapy application, Peter R. Carroll</b>  <b>Advanced Cancer: The improved understanding of androgen signaling in prostate cancer progression, and its clinical application, Eleni Efsthathiou</b>  <b>Advanced Cancer: how to intergrate chemotherapy into the treatment of prostate cancer in the era of "targeted" alternative, Chris Logothetis</b>  <b>Advanced Cancer: The improved understanding of the immunobiology of prostate cancer; and its clinical application, Padamane Sharma</b></p>	
17.15-19.00	<b>MEETING ON THE OCCASION OF EXCELLENCE IN ONCOLOGY</b>			

\*: have been invited

- THORACIC ONCOLOGY
- RADIATION ONCOLOGY
- SCREENING
- GENETICS (& SCREENING)
- GYNAECOLOGICAL CANCER
- GASTROINTESTINAL (NON COLORECTAL)
- IMMUNOLOGY
- GASTROINTESTINAL CANCER (COLORECTAL)
- BREAST CANCER
- HAEMATOLOGICAL MALIGNANCIES
- SARCOMAS
- MELANOMAS
- UROGENITAL CANCER
- NOVEL THERAPEUTICS
- GENETICS
- PSYCHO-ONCOLOGY
- NEURO-ONCOLOGY





**MAIN SCIENTIFIC PROGRAMME**

**Friday, 24 February 2012**

as per 22 November 2011

	HALL I	HALL II	HALL III	HALL IV
8.30-9.30	<p><b>CLINICAL CASE WORKSHOP</b>  <b>Decision making in the treatment of recurrent ovarian cancer</b>                      Moderator: Jonathan Ledermann                      Discussants:  <b>Management of end-stage recurrent ovarian cancer</b>, Marcia Hall  <b>About surgical aspects of recurrent ovarian cancer treatment</b>, Philipp Harter</p>	<p><b>CLINICAL CASE WORKSHOP</b>  <b>Management of 1st line NSCLC after 4 cycles chemotherapy and stable disease</b>                      Moderator: Sanjay Popat                      Discussants:  <b>Maintenance therapy is standard of care</b>, Jan van Meerbeek  <b>Maintenance therapy is not standard of care</b>, Thierry Le Chevalier</p>	<p><b>CLINICAL CASE WORKSHOP</b>  <b>Decision making in prostate cancer progressing on ADT</b>                      Moderator: Chris Logothetis                      Discussants: Peter R. Carroll*, Eleni Efstathiou*, Padamane Sharma*</p>	<p><b>CLINICAL CASE WORKSHOP</b>  <b>Breast Cancer</b>                      Moderator: Stephen Johnston                      Discussant:                      Bhawna Sirohi*</p>
09.30-10.15	<p><b>IPOS SPECIAL SESSION</b>  <b>Current Issues in Oncology</b>  <b>Assesment and Management of Delirium in cancer patients</b>                      Chair: William Breitbart</p>		<p><b>ACS SPECIAL SESSION</b>  <b>Current Issues in Oncology</b>  <b>Update in prostate, lung and cervical cancer</b>                      Chair: J. Leonard Lichtenfeld                      Speakers: Otis Brawley &amp; Robert Smith</p>	<p><b>NSABP SPECIAL SESSION</b>  <b>Milestone research of NSABP</b>                      Speaker: Norman Wolmark</p>
10.15-11.00				
11.00-11.30	<b>COFFEE BREAK</b>			
11.30-12.30	<p><b>EDUCATIONAL SYMPOSIUM</b>  <b>Tumour Immunology</b>                      Chair: Alexander Eggemont  <b>New insights in the role of the immune system in cancer</b>, Cornelis Melief  <b>Chemotherapeutics, Targeted Drugs and Immunogenic Cell Death: the promise of synergy</b>, Laurence Zitvogel*  <b>New insights for developments of cancer vaccines</b>, Giorgio Parmiani  <b>Melanoma, the paradigm tumor for new immunotherapeutic development strategies</b>, Alexander Eggemont</p>		<p><b>CLINICAL CASE WORKSHOP</b>  <b>A cancer patient with intractable pain: the key role of palliative care</b>                      Speaker: Janet Abraham</p>	
12.30-13.30			<p><b>CLINICAL QUESTIONS FOR PROSTATE CANCER - SESSION II</b>                      Chair: Chris Logothetis                      Speakers:  <b>Intermittent vs Continuous androgen ablation</b>, Peter R. Carroll and Chris Logothetis  <b>Immediate treatment vs Watchful waiting</b>, Chris Logothetis and Peter R. Carroll</p>	
13.30-14.30	<p><b>WORKSHOP SESSION</b>  <b>The direction of molecular imaging for the clinic in the next 5-10 years</b>                      Chair: Gordon McVie                      Speakers:  <b>Labelling of bifunctional antibodies-dock and lock to unlock the potential of molecular imaging</b>, David Goldenberg  <b>What we have learnt from combining diagnostic and therapeutic molecular imaging</b>, Elizabeth DeVries  <b>Why has PET failed to achieve its full potential</b>, Terry Jones</p>			
14.30-15.30	<b>LUNCH BREAK</b>			
15.30-16.30	<p><b>CLINICAL QUESTIONS FOR MELANOMA</b>                      Chair: Keith Flaherty                      Speakers:  <b>Is it time for the incorporation of BRAF targeted therapies into standard practice?</b>, James Larkin*  <b>What is the role of novel immunotherapy in the treatment of melanoma?</b>, Caroline Robert*  <b>Is a history of ulcerated primary melanoma the only indication for adjuvant interferon therapy?</b>, Lex Eggemont</p>		<p><b>CLINICAL QUESTIONS FOR THORACIC ONCOLOGY</b>                      Chair: Sanjay Popat                      Speakers:  <b>Current management of advanced neuroendocrine-differentiated NSCLC</b>, Ken O'Byrne  <b>Current systemic therapy for mesothelioma</b>, Paul Baas</p>	
16.30-17.30			<p><b>CLINICAL QUESTIONS FOR OVARIAN CANCER</b>                      Chair: Jonathan Ledermann                      Speakers:  <b>New pathology of ovarian cancer and biomarker driven research</b>, Glenn McLuggage*  <b>PARP inhibitors in ovarian cancer</b>, Jonathan Ledermann  <b>Treatment of endometrial cancer; role of systemic therapy and radiation</b>, Nicholas Reed</p>	
17.30-19.30	<b>MEETING ON THE OCCASION OF EXCELLENCE IN ONCOLOGY</b>			

\*: have been invited

- THORACIC ONCOLOGY
- RADIATION ONCOLOGY
- SCREENING
- GENETICS (& SCREENING)
- GYNAECOLOGICAL CANCER
- GASTROINTESTINAL (NON COLORECTAL)
- IMMUNOLOGY
- GASTROINTESTINAL CANCER (COLORECTAL)
- BREAST CANCER
- HAEMATOLOGICAL MALIGNANCIES
- SARCOMAS
- MELANOMAS
- UROGENITAL CANCER
- NOVEL THERAPEUTICS
- GENETICS
- SURGICAL ONCOLOGY
- PSYCHO-ONCOLOGY
- NEURO-ONCOLOGY





**MAIN SCIENTIFIC PROGRAMME**

**Saturday, 25 February 2012**

as per 22 November 2011

	HALL I	HALL II	HALL III	HALL IV
8.30-9.30	<p><b>KEYNOTE LECTURE</b> Prevention and management of venous thrombosis in cancer patients Speaker: Kelvin Hong</p>	<p><b>MEET THE EXPERT SESSION</b> Novel targets in mCRC; molecular based decision making, platforms for innovative designs Speaker: Scott Kopetz</p>	<p><b>MEET THE EXPERT SESSION</b> New trends in chemotherapy of sarcomas Speaker: Jean-Yves Blay*</p>	<p><b>MEET THE EXPERT SESSION</b> Lynch syndrome/ mismatch repair genes and choice of Chemotherapy Speaker: Astrid Stormorken</p>
9.30-11.00	<p><b>CURRENT ISSUES IN ONCOLOGY</b> Peritoneal Carcinomatosis Chairs: Dirk Arnold and Pompiliu Piso Speakers: Colorectal cancer, Pompiliu Piso Prevention and treatment of peritoneal carcinomatosis in gastric cancer: role of HIPEC, Olivier Glehen Ovarian cancer, Oliver Zivanovic Pseudomyxoma peritonei, Brendan J. Moran Multimodal palliative treatment with intraperitoneal administration of monoclonal antibodies, Dirk Arnold</p>		<p><b>CLINICAL QUESTIONS FOR RADIOTHERAPY</b> Chair: Harry Bartelink Speakers: The role of micro arrays in predicting radiotherapy outcome, Marc van de Vijver The role of biological agents in combination with Radiotherapy, to be announced The role of hypoxia in radiation oncology, Jens Overgaard* The role of image guided radiotherapy, to be announced</p>	
11.00-11.30	<b>COFFEE BREAK</b>			
11.30-12.30	<p><b>CLINICAL QUESTIONS FOR BREAST CANCER</b> Chair: Stephen Johnston Co-chairperson: Katerina Kotsori Speakers: Will PARP inhibitors work for triple negative breast cancer?, Andy Tutt* Can gene arrays provide helpful information for the treatment of breast cancer?, Fatima Cardoso What is the role of PET imaging in the treatment of advanced breast cancer?, Pat Price Which patients need adjuvant taxanes?, Paul Ellis* Is tamoxifen still a useful drug, and if so for whom?, Kathy Pritchard</p>	<p><b>CLINICAL CASE WORKSHOP</b> A cancer patient with intractable pain: the key role of palliative care, Janet Abraham Honorary Co-chairman: Ozgur Ozyilcan</p>	<p><b>CLINICAL QUESTIONS FOR CNS TUMOURS</b> Chair: Evanthia Galanis Speakers: What is new in the management of CNS lymphoma?, Patrick Wen What is new in the management of gliomas?, Evanthia Galanis What is new in the management of CNS metastases?, David Reardon</p>	
12.30-13.15	<p><b>KEYNOTE LECTURE</b> Practice applied genomics Speaker: Norman Wolmark</p>		<p><b>SCIENTIFIC SYMPOSIUM</b> The concept of genetic susceptibility and the screening of high risk individuals Chair: Angelo Paradiso Speakers: Who to screen?, Bernardo Bonanni Treatment of hereditary breast cancer, Alain Fourquet Genetic counselling, Silvia Formenti Round table discussion, Silvia Formenti, Angelo Paradiso, Narod*, T. Byrski*</p>	
13.15-14.00	<p><b>DEBATE</b> Do angiogenesis inhibitors add anything but cost to current treatment of breast cancer? Moderator: Paul Ellis Speakers: PRO, Norman Wolmark CON, David Miles*</p>			
14.00-15.00	<b>LUNCH BREAK</b>			
15.00-16.00	<p><b>CLINICAL QUESTIONS FOR LIVER METASTASES IN COLON CANCER</b> Chair: Dirk Arnold Speakers: Surgery alone is the treatment of choice, Ulf Neumann* The role of adjuvant treatment, Emmanuel Mitry</p>			

\*: have been invited

- THORACIC ONCOLOGY
- RADIATION ONCOLOGY
- SCREENING
- GENETICS (& SCREENING)
- GYNAECOLOGICAL CANCER
- GASTROINTESTINAL (NON COLORECTAL)
- IMMUNOLOGY
- GASTROINTESTINAL CANCER (COLORECTAL)
- BREAST CANCER
- HAEMATOLOGICAL MALIGNANCIES
- SARCOMAS
- MELANOMAS
- UROGENITAL CANCER
- NOVEL THERAPEUTICS
- GENETICS
- SURGICAL ONCOLOGY
- PSYCHO-ONCOLOGY
- NEURO-ONCOLOGY





# EXCELLENCE in **Oncology**

Translating research into best patient care

**22-25**

FEBRUARY 2012



**ISTANBUL, TURKEY**

**INSTITUTE OF EXCELLENCE IN ONCOLOGY WORKSHOPS**

**Wednesday, 22 February 2012**

as per 22 November 2011

Half day afternoon programme

**14.00 – 18.00**

## **EXCELLENCE IN ONCOLOGY WORKSHOPS ON:**

- how to competently write and present a case study and/or clinical research at international meetings
- how to apply for grant or bursary award
- providing mentoring advice and support on career development.

## **WORKSHOPS TOPICS**

- 1 Breast cancer**
- 2 Lung cancer**
- 3 Gynaecological cancer**
- 4 Genitourinary cancer**

## **Workshops Chairman:**

**Prof Christopher Logothetis**, MD Anderson Cancer Center, USA Faculty Chairman

## **Faculty**

**Prof Stephen Johnston**, Royal Marsden Hospital Hospital, UK

**Prof Jonathan Ledermann**, UCL Cancer Research UK Centre, UK

**Dr Gary Middleton**, Royal Surrey County Hospital NHS Foundation Trust, UK





# EXCELLENCE in **Oncology**

Translating research into best patient care

22-25

FEBRUARY 2012

ISTANBUL, TURKEY

**EXCELLENCE IN ONCOLOGY SUMMIT**

**Thursday, 23 February 2012**

as per 22 November 2011

## Addressing the Challenges of Personalised Medicine

**17:00 – 20:00**

The Institute of Excellence in Oncology has decided to instigate a constructive dialogue between the key opinion leaders in oncology and those in the Pharma industry. The purpose of the Summit is to identify current problems, suggest credible solutions and formulate how best to implement them in the current environment. This 3-hour dialogue will take place in Istanbul, in February 2012 with a focus on the topic of personalised medicine. It aims to be an open exchange of ideas with a view to creating opportunity to make advances in realising the potential of personalised medicine in the treatment of cancer. Ultimately, the long-term vision of the Summit is to incorporate the involvement of other stakeholders, such as patient groups and policymakers, to actively develop an effective policy framework that is based on the recommendations of our ongoing stakeholder-led discussions.

### The format of the Summit will include:

- Introductory remarks from the Co-chairs of the Summit Steering Committee
- An opening presentation on the latest advances in personalised medicine
- Small workgroups each covering one of the 5 subtopics mentioned below
- Boardroom discussion for all participants to reflect on the workgroup conclusions
  1. Molecular Diagnostics – from molecular signature to therapeutic choice
  2. Realising the promise of stratified and personalised Medicine
  3. Parallel drug-diagnostics as the norm for new anti-cancer drugs
  4. Understand the pathophysiology and mechanisms of action at the molecular level
  5. Optimising resources on the right interventions for responsive patients

The meeting has been developed by:

#### **Prof Christopher Logothetis**

Chairman, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, USA

#### **Prof Matti Aapro**

Dean of the Multidisciplinary Oncology Institute, Clinique de Genolier, Switzerland.

